Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1411 AL 1425

Zoophilia and Parkinson's disease

Almeida KJ, de Oliveira Filho MC, Lopes Nery PC, Guimarães Silva JS, Campos Sousa RN.

Parkinsonism Relat Disord. 2013 Dec;19(12):1167-8. doi: 10.1016/j.parkreldis.2013.07.015. Epub 2013 Aug 22.

Infantile parkinsonism and GABAergic hypotransmission in a patient with pyruvate carboxylase deficiency

Ortez C, Jou C, Cortès-Saladelafont E, Moreno J, Pérez A, Ormazábal A, Pérez-Cerdá C, Pérez B, Artuch R, Cusi V, García-Cazorla A.

Gene. 2013 Dec 15;532(2):302-6. doi: 10.1016/j.gene.2013.08.036. Epub 2013 Aug 23.

SUMO and Parkinson's disease

Eckermann K.

Neuromolecular Med. 2013 Dec;15(4):737-59. doi: 10.1007/s12017-013-8259-5. Epub 2013 Aug 25.

Scientific evaluation and pricing of medical devices and associated procedures in France

Gilard M, Debroucker F, Dubray C; Participants of round table N°1 of Giens Workshops XXVIII(th); Allioux Y, Aper E, Barat-Leonhardt V, Brami M, Carbonneil C, Chartier-Kastler E, Coqueblin C, Fare S, Giri I, Goehrs JM, Levesque K, Maugendre P, Parquin F, Sales JP, Szwarcensztein K.

Therapie. 2013 Jul-Aug;68(4):193-208. doi: 10.2515/therapie/2013036. Epub 2013 Aug 28.

New perspectives in nuclear neurology for the evaluation of Parkinson's disease

Benadiba M, Luurtsema G, Tumas V, Buchpigel CA, Busatto GF.

J Parkinsons Dis. 2013 Jan 1;3(3):301-23. doi: 10.3233/JPD-130207.

Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications

Willard SS, Koochekpour S.

Int J Biol Sci. 2013 Aug 9;9(7):728-42. doi: 10.7150/ijbs.6475. eCollection 2013.

Sulforaphane as a potential protective phytochemical against neurodegenerative diseases

Tarozzi A, Angeloni C, Malaguti M, Morroni F, Hrelia S, Hrelia P.

Oxid Med Cell Longev. 2013;2013:415078. doi: 10.1155/2013/415078. Epub 2013 Jul 25.

SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration

Milani P, Ambrosi G, Gammoh O, Blandini F, Cereda C.

Oxid Med Cell Longev. 2013;2013:836760. doi: 10.1155/2013/836760. Epub 2013 Jul 28.

Can we teach old dogs new tricks? Neuroprotective cell therapy in Alzheimer's and Parkinson's disease

Kazmerova Z, Zilka N, Cente M, Neradil P, Zilkova M, Novak M.

J Alzheimers Dis. 2013;37(2):251-72. doi: 10.3233/JAD-130572.

Renal dopamine receptors, oxidative stress, and hypertension

Cuevas S, Villar VA, Jose PA, Armando I.

Int J Mol Sci. 2013 Aug 27;14(9):17553-72. doi: 10.3390/ijms140917553.

High-dose thiamine as initial treatment for Parkinson's disease

Costantini A, Pala MI, Compagnoni L, Colangeli M.

BMJ Case Rep. 2013 Aug 28;2013:bcr2013009289. doi: 10.1136/bcr-2013-009289.

[Impulsive-compulsive behaviours in a German Parkinson's disease outpatient sample]

Rohde K, Riedel O, Lueken U, Rietzel S, Fauser M, Ossig C, Reichmann H, Storch A.

Fortschr Neurol Psychiatr. 2013 Sep;81(9):503-10. doi: 10.1055/s-0033-1350457. Epub 2013 Aug 28.

Pesticide-induced gene mutations and Parkinson disease risk: a meta-analysis

Liu X, Ma T, Qu B, Ji Y, Liu Z.

Genet Test Mol Biomarkers. 2013 Nov;17(11):826-32. doi: 10.1089/gtmb.2013.0313. Epub 2013 Aug 29.

Idiopathic Parkinson's disease phenotype related to C9ORF72 repeat expansions: contribution of the neuropsychological assessment

Annan M, Beaufils É, Viola UC, Vourc'h P, Hommet C, Mondon K.

BMC Res Notes. 2013 Aug 29;6:343. doi: 10.1186/1756-0500-6-343.

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT)

van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR; IMPACT study group.

Lancet Neurol. 2013 Oct;12(10):947-56. doi: 10.1016/S1474-4422(13)70196-0. Epub 2013 Aug 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias